Making stem cell models from blood of people with systemic sclerosis
Blood samples are turned into stem cells to study systemic sclerosis in the lab.
Plain-language title generated from the registry record
Registry title: Tissue Modeling in Systemic Sclerosis Using Induced Pluripotent Stem Cells (iPSCs)
Key facts
- Where
- Montpellier, FranceSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT07650565, who can take part
Where in France
- University Hospital, MontpellierMontpellier, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Montpellier
- Trial code
- NCT07650565
- Record updated
- 29 October 2026
- Original description
The objective of the study is to establish an in vitro model using iPSCs to test the hypotheses developed.Read full original descriptionShow less
Tissue Modeling in Systemic Sclerosis Using Induced Pluripotent Stem Cells (iPSCs)
The objective of the study is to establish an in vitro model using iPSCs to test the hypotheses developed.
The primary objective is to generate, via the SAFE-IPS platform, 8 iPSC lines derived from blood samples taken from:
* Two patients with severe/diffuse SSc with multi-organ involvement (with anti-SCl-70 autoantibodies) * Two of their healthy close relatives * Two patients with uncomplicated SSc with localized involvement (with non-SCl-70 autoantibodies) * Two of their healthy close relatives
These 8 cell lines will be differentiated by several teams at the FHU REGENHAB into:
* Immune cells (monocytes/macrophages, neutrophils, dendritic cells, B/T lymphocytes) * Mesenchymal stromal cells * Myocardial cells * Skin cells (fibroblasts) * Synovial cells * Bronchial cells * Endothelial cells
This project aims to map cellular and tissue heterogeneity using iPSC lines obtained from patients with both severe and mild SSc, employing single-cell RNA-seq under various pathological conditions, with and without autologous (or even heterologous) autoimmune stimulation. For example, the percentages of different cell types comprising a tissue in these various situations will be calculated. Comparisons will be made with control groups using healthy iPSC lines by recruiting healthy subjects with the same genetic profile and gender as the patients.
Inclusion: Age between 18 and 85 years; Diagnostic criteria for the three groups:; > Severe SSc group:; Diagnosis of diffuse/severe systemic sclerosis by a physician for at least 12 months based on recommendations (according to ACR criteria); Known positivity of autoimmunity directed against Scl-70; > Localized/non-complicated SSc group:; Diagnosis of systemic sclerosis by a physician for at least 12 months based on recommendations (according to ACR criteria); Documentation of the absence of major vital organ involvement; Negative anti-Scl-70 autoantibodies but presence of other systemic sclerosis-related autoantibodies; > Healthy subjects group:; First-degree relative of a patient recruited in one of the systemic sclerosis groups (father, mother, brother, sister, adult child); Absence of systemic autoimmune diseases.
Exclusion: Other diseases that may affect erythroid progenitor cells (non-exhaustive: active cancer, hematological malignancy, chemotherapy targeting DNA); Patient in an exclusion period determined by another protocol; Protected populations according to French public health law (pregnant or breastfeeding women; individuals deprived of liberty by judicial or administrative decision; adults under legal protection (any form of guardianship)); Absence of informed consent; Not affiliated with a national health insurance system.